Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Drug Resistance, Neoplasm
  • Gene Expression Profiling
  • Interferon-alpha
  • Kidney Neoplasms

abstract

  • In a randomized phase III trial, sunitinib was associated with significantly superior progression-free survival when compared with interferon alfa as first-line therapy in patients with metastatic renal cell carcinoma. This article investigates whether baseline quality of life and demographic and clinical variables were predictive for progression-free survival.

publication date

  • October 13, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2790652

Digital Object Identifier (DOI)

  • 10.1200/JOP.0922004

PubMed ID

  • 20856722

Additional Document Info

start page

  • 66

end page

  • 70

volume

  • 5

number

  • 2